GL Pharm Tech has been growing earnings at an average annual rate of 26.9%, while the Pharmaceuticals industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 23.9% per year.
How GL Pharm Tech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A204840 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
36,862
-132
12,349
1,566
31 Dec 25
35,268
12
11,607
1,916
30 Sep 25
34,299
307
11,223
2,582
30 Jun 25
29,445
57
10,557
1,609
31 Mar 25
28,053
-681
9,639
1,754
31 Dec 24
26,048
-2,337
9,157
2,325
30 Sep 24
24,900
-3,418
9,072
2,048
30 Jun 24
27,909
-4,264
8,609
2,862
31 Mar 24
26,761
-4,783
8,972
3,146
31 Dec 23
26,033
-3,749
9,012
2,377
30 Sep 23
25,081
-2,389
8,041
2,437
30 Jun 23
22,095
-1,679
7,360
2,306
31 Mar 23
19,325
797
5,987
1,883
31 Dec 22
16,729
-790
5,684
1,968
30 Sep 22
14,466
-1,602
5,003
2,396
30 Jun 22
12,271
-2,757
4,728
2,796
31 Mar 22
11,942
-4,502
4,454
2,732
31 Dec 21
12,426
-3,727
3,190
2,974
30 Sep 21
11,652
-4,082
3,340
2,383
30 Jun 21
11,725
-3,371
3,132
2,189
31 Mar 21
12,182
-3,599
3,070
2,684
31 Dec 20
11,988
-3,356
3,104
2,518
30 Sep 20
9,630
-3,648
2,429
2,666
30 Jun 20
9,772
-4,180
2,500
2,487
31 Mar 20
10,029
-6,967
2,472
2,296
31 Dec 19
10,608
-5,515
2,488
2,221
30 Sep 19
12,226
-5,505
2,775
2,014
30 Jun 19
10,911
-5,844
3,170
1,538
31 Mar 19
9,668
-3,369
2,938
1,817
31 Dec 18
7,998
-5,350
3,295
1,680
30 Sep 18
6,487
-4,619
2,858
1,720
30 Jun 18
5,446
-4,105
2,154
2,138
31 Mar 18
3,826
-4,310
2,118
1,550
31 Dec 17
2,414
-4,237
1,466
1,459
Quality Earnings: A204840 is currently unprofitable.
Growing Profit Margin: A204840 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A204840 is unprofitable, but has reduced losses over the past 5 years at a rate of 26.9% per year.
Accelerating Growth: Unable to compare A204840's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A204840 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.5%).
Return on Equity
High ROE: A204840 has a negative Return on Equity (-0.66%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/12 19:31
End of Day Share Price
2026/06/12 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GL Pharm Tech Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.